Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Exercise As Intervention in Chronic Lymphocytic Leukemia [NA]
A clinical trial sponsored by Universidade do Porto is evaluating exercise as an intervention for Chronic Lymphocytic Leukemia and is curren…
-
CLINICAL_TRIALS trial_result · 2025-03-17Clinical Trial Update: Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia [Phase 3]
A Phase 3 study evaluating acalabrutinib in patients with chronic lymphocytic leukemia has completed.
-
CLINICAL_TRIALS research · 2025-03-14Clinical Trial Update: Study on the Diagnosis and Management of CLL in Italy by GIMEMA
Ongoing Italian study by GIMEMA recruiting to improve diagnosis and management of chronic lymphocytic leukemia and related conditions (inclu…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]
Phase 3 trial comparing pirtobrutinib (LOXO-305) against investigator's choice (idelalisib plus rituximab or bendamustine plus rituximab) in…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning with fludarabine and melphalan plus total body irradiation for haploidentical stem c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-03-07Clinical Trial Update: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas [Phase 1]
A Phase 1 study of CG-806 in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and non-Hodgkin's lymphomas ha…
-
FDA approval · 2025-03-03FDA Approved: LENALIDOMIDE — Original Application (BIOCON PHARMA INC.,)
FDA approved Biocon Pharma Inc.'s lenalidomide as an original ANDA, enabling a generic version of the cancer drug. Indications include multi…
-
CLINICAL_TRIALS withdrawal · 2025-02-28Clinical Trial Update: Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation [Phase 1]
Phase 1 trial of ipilimumab, ibrutinib, and nivolumab for chronic lymphocytic leukemia and Richter transformation has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL [Phase 2]
Phase 2 trial evaluating the AU2 combination (acalabrutinib, umbralisib, and ublituximab) in relapsed and untreated chronic lymphocytic leuk…
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide [Phase 2]
A Phase 2 trial evaluating the incidence of hepatitis B in HBsAg-positive patients with diffuse large B-cell lymphoma or chronic lymphocytic…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies [Phase 1]
Phase 1 clinical trial update for BP1002 in advanced lymphoid malignancies across several B-cell and T-cell lymphomas; trial status is activ…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
This clinical trial update announces a study of lisocabtagene maraleucel for relapsed/refractory Chronic Lymphocytic Leukemia and Small Lymp…
-
CLINICAL_TRIALS trial_result · 2025-02-20Clinical Trial Update: Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers [Phase 1]
This is a completed Phase 1 safety study of navitoclax (ABT-263) in combination with rituximab for CD20-positive lymphoid malignancies, incl…
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia Patients [EARLY_Phase 1]
A Phase 1 EARLY study is evaluating the effects of a strength-based physical exercise program in patients with chronic lymphocytic leukemia;…
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL [Phase 1]
Phase 1 study update for ONO-7018 in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia, assessing safety, tolerabili…
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies [Phase 1, Phase 2]
This completed Phase 1/2 trial evaluates the combination of cirmtuzumab and ibrutinib in patients with B-cell lymphoid malignancies, includi…
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
This clinical trial update describes the PRO SID Project, which aims to develop and validate a patient-reported outcome screening measure fo…
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction [Phase 1]
Phase 1 clinical trial update of romidepsin for patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction…
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL [Phase 1]
This is a Phase 1 clinical trial evaluating the combination of pembrolizumab with TGR-1202 (umbralisib) in relapsed/refractory chronic lymph…
-
CLINICAL_TRIALS trial_result · 2025-02-04Clinical Trial Update: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies [Phase 1]
Phase 1 VENOM trial evaluating venetoclax with obinutuzumab and magrolimab in relapsed and refractory indolent B-cell malignancies has compl…
-
CLINICAL_TRIALS research · 2025-02-03Clinical Trial Update: Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India
A retrospective medical chart review from India evaluating outcomes of chronic lymphocytic leukemia and mantle cell lymphoma patients treate…
-
CLINICAL_TRIALS withdrawal · 2025-02-03Clinical Trial Update: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma [Phase 1]
A Phase 1 clinical study evaluating duvortuxizumab plus ibrutinib in lymphomas has been withdrawn.
-
FDA approval · 2025-01-31FDA Approved: LENALIDOMIDE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC's generic lenalidomide (LENALIDOMIDE) under an Original Application (ANDA 216213).
-
CLINICAL_TRIALS trial_result · 2025-01-30Clinical Trial Update: Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia [Phase 3]
A Phase 3 study comparing acalabrutinib to chlorambucil plus rituximab in adults with previously untreated chronic lymphocytic leukemia has …
-
CLINICAL_TRIALS trial_result · 2025-01-29Clinical Trial Update: Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial update reporting on the combination of Ofatumumab and Ibrutinib with allogeneic bone marrow transplant or consolidation in hig…